Methylation of Epstein-Barr Virus-Associated Gastric Cancer Suppressor Genes

Tingting Chen¹, *, Donghui Tian², Yurong Zhang³

¹Department of Gastroenterology, Binzhou People's Hospital, Binzhou City, P. R. China
²Department of Neurology, Binzhou People's Hospital, Binzhou City, P. R. China
³Department of Hepatobiliary Surgery, Binzhou People's Hospital, Binzhou City, P. R. China

Email address:
TingtingChen2019@163.com (Tingting Chen)
*Corresponding author

To cite this article:

Received: May 29, 2019; Accepted: July 25, 2019; Published: July 29, 2019

Abstract: Objective: To identify the methylation silenced tumor suppressor genes in Epstein-Barr virus (EBV)-associated gastric cancer (EBVaGC). Methods: EBV-positive (GT38, PT and SNU719) and negative (SGC7901) gastric cancer cell lines were selected and treated with 5-Aza-CdR. Then real-time fluorescence quantitative PCR was used to validate the results of microarray, and methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS) were adopted to detect the CpG island methylation levels of gene promoters. Results: The expression levels of 6 differentially expressed genes (H19, LOXL1, ARMCX2, LXN, CDH3 and MMP7) before and after 5-Aza-CdR treatment were confirmed by real-time qPCR, which are consistent with the results of microarray analysis. There were different degrees of methylation in LOXL1 gene promoter in EBVaGC. GT38 and PT were fully methylated, and SGC7901 and HGC-27 was unmethylated, suggesting that this gene is a candidate methylation silenced tumor suppressor gene. The methylation rate of LOXL1 in EBVaGC was significantly higher than that in EBV-negative gastric cancer (EBVnGC). Conclusion: The promoter region of candidate tumor suppressor gene LOXL1 shows high methylation status, indicating that EBV critically accounts for the methylation of LOXL1 gene regulatory region. EBV is involved in the pathogenesis of EBVaGC that aberrant methylation occurred in promoter CpG island, which inactivates tumor suppressor genes.

Keywords: Epstein-Barr Virus, Gastric Cancer, Methylation, Tumor Suppressor Gene

1. Introduction

Epstein-Barr virus (EBV), the strain of which was successfully established by Epstein and Barr for the first time in 1964 by the in vitro suspension culture of Burkitt African children lymphoma cells, leads to a variety of malignancies (e.g. nasopharyngeal carcinoma) [1]. EBV mainly infects B lymphocytes manifested with non-proliferation infection [2], and stratified squamous epithelial cells accompanied by viral replication inducing B cell-derived tumors and epithelial cell-derived tumors [3]. The disease is widely distributed worldwide and may be epidemic because more than 90% of healthy adults are carrying this virus [4]. The onset ages range mostly between 15 and 30 years old, and children below 6 often show inapparent infection. EBV-related diseases occur throughout the year, which seems to peak in late autumn and early winter. Once infected, the patients usually get relatively long-lasting immunity. The relationship between EBV infection and gastric cancer was confirmed in the 1990s. The EBV infection rate of lymphoepithelioma-like gastric cancer is up to 80% to 100%, and there that of ordinary gastric cancer differs regionally by about 10% [5]. DNA methylation is the most cutting-edge epigenetic mechanism, in which the role of methylation-based epigenetic change in tumorigenesis is of the greatest concern. In addition to mutation and deletion, the hypermethylation of tumor suppressor gene promoter is considered to dominate the inactivation of tumor suppressor gene, which plays an important role in the occurrence and development of tumor [6]. About 20% of human tumors are related to viral infections. The abnormal epigenetics of host
cell caused by virus infections has been spotlighted in the current research on the carcinogenic mechanism of tumor virus [7].

Studies have shown that hypermethylation of some tumor-related genes [8] (tumor suppressor gene, apoptosis-related gene and mismatch repair gene, etc.) exists in EBV-associated gastric cancer (EBVaGC), whose methylation frequency and methylation density of promoter CpG island are higher than those of EBV-negative gastric cancer (EBVnGC). High methylation is negatively correlated with the expression of tumor suppressor genes in EBVaGC, such as p16 and p73. EBV infection induces aberrant methylation in CpG island that inactivates cancer suppressor genes, which may be the mechanism of EBV involved in the occurrence of EBVaGC. However, the relationship between EBV genome methylation and host cell gene methylation, as well as how EBV induces the methylation of suppression cancer genes of host cell have not been clarified yet [9].

EBV-positive and-negative gastric cancer cell lines were selected as the object in this study, which were treated with 5-Aza-CdR [10] to induce the re-expression of methylation silenced tumor suppressor genes, and an untreated control group was established simultaneously. The methylation statuses of target genes in EBVaGC and EBVnGC were detected and compared, and the relationship between the methylation of cancer suppressor genes and clinical-pathological characteristics were further analyzed and identified define EBVaGC-specific apparent molecular genetic marker.

2. Materials and Methods

2.1. Apparatus

The apparatus included PTC-100 PCR, ABI-7000 quantitative fluorescence PCR (ABI), spectrophotometer, high-speed low-temperature centrifuge (Eppendor), CO₂ incubator (SHEIL-LAB), G2545 A hybrid reactor, G2565BA microarray scanner (Agilent), inverted microscope, glass tube incubator (SHEIL-LAB), G2545A hybrid reactor, G2565 BA medium, TRIzol and fetal bovine serum were purchased from Gibco. 5-aza-deoxycytidine was purchased from Sigma. Microarray hybridization reagents were bought from Agilent. The other reagents and materials include AM8436 aUTP (Alnbion), 0.2 ml PCR reaction tube, 15 ml centrifuge tube, 1 ml and 1.5 ml Eppendor tubes, PCR reagents (dNTP, MgCl₂, 10×-buffer), trypsin, agarose and DNA marker DL-2000.

2.2. Reagents and Materials

EBV cells were stored in our laboratory. DMEM culture medium, TRIzol and fetal bovine serum were purchased from Gibco. 5-aza-deoxycytidine was purchased from Sigma. Microarray hybridization reagents were bought from Agilent. The other reagents and materials include AM8436 aUTP (Alnbion), 0.2 ml PCR reaction tube, 15 ml centrifuge tube, 1 ml and 1.5 ml Eppendor tubes, PCR reagents (dNTP, MgCl₂, 10×-buffer), trypsin, agarose and DNA marker DL-2000.

2.3. Cell Culture and Treatment

DMEM medium was used to cultivate 4 cell lines (GT38, PT, SNU719 and SGC7901), subcultured once every 2 to 3 days. 5 mg was then taken and fully dissolved with DMEM medium, allowing the constant volume to 43.8 mL, which was prepared into a 500 µmol/L mother liquor and stored at -20°C. Then it was diluted to a 10 µmol/L working solution by DMEM medium. The cells in logarithmic growth phase were sampled. When the cell convergence concentration reached 70%--80%, the medium was abandoned and the cells were washed twice with PBS. DMEM medium of 5-Aza-CdR containing 10 µmol/L methylation inhibitor was added, and the group without drug was used as the control. The total cellular RNA was extracted after 4 continuous days.

2.4. Differentially Expressed Genes Identified by Real-Time qPCR

The total cellular RNA was extracted for RNA inverse transcription according to the standard conditions required by reverse transcription kit. cDNA obtained from inverse transcription was used as the template for PCR reaction and stored at -20°C. Amplification and data analysis were conducted on a LightCycler480 II fluorescent quantitative PCR instrument with the SYBR Green I dye method. The result data of Real-time qPCR were analyzed to determine the Ct value of each group. Ct value represents the number of cycles experienced when fluorescence signal in each reaction tube reached the specified threshold. Ct value of each template is linearly correlated with the logarithm of initial copy number of the template. ΔCt value of each sample was analyzed with the relative quantitative method and ΔCt=target gene Ct - internal reference gene Ct. 2^{ΔΔCt} was calculated according to ΔΔCt=treatment group - control group ΔCt. When the amplification efficiencies of target and internal reference genes are close, 2^{ΔΔCt} represents the times of expression of target gene in the sample in the treatment group relative to that in the control group (Table 1).

<table>
<thead>
<tr>
<th>Gene</th>
<th>Type</th>
<th>Sequence</th>
<th>Annealing temperature (°C)</th>
<th>Length (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H19</td>
<td>Primer 1</td>
<td>GGCCCTTCGTAGACACCTTAG</td>
<td>56</td>
<td>142</td>
</tr>
<tr>
<td>ARMCX2</td>
<td>Primer 2</td>
<td>TAGAGTGATTAGACACATT</td>
<td>58</td>
<td>142</td>
</tr>
<tr>
<td>LOXL1</td>
<td>Primer 1</td>
<td>CTGCCCTTTGAAGCTACGAG</td>
<td>59</td>
<td>121</td>
</tr>
<tr>
<td>LXN</td>
<td>Primer 1</td>
<td>ATGGTGAGCTGAAGCTACGAC</td>
<td>58</td>
<td>81</td>
</tr>
<tr>
<td>MMP7</td>
<td>Primer 1</td>
<td>TGCATGAGCTGAAGCTACGAC</td>
<td>58</td>
<td>128</td>
</tr>
<tr>
<td></td>
<td>Primer 2</td>
<td>TGCATGAGCTGAAGCTACGAC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Primer sequences of real-time qPCR detection.
2.5. DNA Methylation

Fresh gastric cancer and corresponding pericarcinomatous tissues resected from 975 gastric cancer patients in our hospital were collected. The tumor was taken immediately after being separated from the body under aseptic conditions. A tissue block with the size of 1 cm$^3$ was taken from the non-necrotic tumor tissue, placed in a sterile bottle and treated as soon as possible or stored at -80°C. Tissue DNA was routinely extracted with the phenol-chloroform-isomyl alcohol method. Meanwhile, part of tissues were taken from each sample, fixed with PBS-10% formalin and embedded with paraffin to prepare tissue sections for pathological diagnosis and EBER in-situ hybridization to screen EBVaGC. 23 cases of EBVaGC sample with strong EBER in-situ hybridization signal and high quality DNA were selected as the positive EBV group and 22 cases of EBVnGC sample were rendered as the negative ENV group.

Nucleic acid was extracted from fresh gastric cancer tissue and corresponding pericarcinomatous tissue cells, and the extracted DNA was modified and purified by nitrate. MSP was conducted on EBV positive gastric cancer cell lines modified by utilizing hydrosulfite, EBV negative gastric cancer cell lines and tissue DNA as the templates. The methylation-specific primers, non-methylation-specific primers and the sizes of MSP products are shown in Table 2. To further detect the specific methylation status at CpG locus in the promoter region of LOXLI coding gene and verify the MSP results, primer line BGS sequences outside MSP primer sequence were designed online using MethPrimer. The results were recorded by a UV gel imaging system.

2.6. Statistical Analysis

The gene promoter methylation detection data were analyzed by PPMS1.5. The measurement data were compared by the calibration test. P=0.5 was considered statistically significant.

3. Results

3.1. Differentially Expressed Genes Identified by Real-Time qPCR

To verify the differential genes identified by gene chip analysis and preliminarily screen methylation silenced genes, 6 differentially expressed genes (H19, LOXL1, ARMCX2, LNX, CDH3 and MMP7) were selected for real-time qPCR. The results of real-time qPCR show that the 6 genes above in three EBV positive gastric cancer cell lines treated with Aza had different degrees of expression up-regulation. However, 5 genes (LOXL1, ARMCX2, LNX, CDH3 and MMP7) in EBV negative gastric cancer cell line SGC7901 have undifferentiated expression before and after Aza treatment, which is consistent with the result of gene chip. Only the expression of H19 gene up-regulated after treating EBV negative gastric cell line SGC7901, which is different from the result of gene chip detection. The comparisons between real-time qPCR and fold change values of chip detection are summarized in Table 3.

3.2. Candidate Tumor Suppressor Genes Promoter Methylation Detection

The MSP results show that LOXL1 gene promoter was highly methylated in GT38 and PT cell lines. Methylation and non-methylation were simultaneously detected in most cell lines, but methylation was not found in SGC7901 and HGC-27 cell lines. The results are exhibited in Figure 1.
In the 23 cases of EBVaGC tissue, two MSP types were detected in LOXL1 coding gene promoter, including 12 cases of type M (12/23, 54.5%) and 11 cases of type M+U (11/23, 45.5%). Two MSP types were detected in the 22 cases of EBVnGC pericarcinomatous tissue, including 1 case of type M+U (1/23, 4.3%) and 22 cases of type U (22/23, 95.7%). In the 22 cases of EBVnGC tissue, two MSP types were detected in LOXL1 coding gene promoter, including 15 cases of type M+U (15/22, 68.2%) and 5 cases of type U (7/22, 31.8%). Two MSP types were detected in the 22 cases of EBVnGC tissue, including 2 case of type M+U (2/22, 9.1%) and 20 cases of type U (20/22, 90.9%). The MSP detections of LOXL1 coding gene promoter in EBVaGC and EBVnGC tissues are shown in Figure 2.

BGS detected the methylation status of LOXL1 gene promoter of some samples. The sequencing results prove that in the 5 cases of EBV positive sample (GT38, PT, Akata, GC89 and GC95) with type M MSP result, most sites at CpG site in LOXL1 promoter region were methylated. In the 4 cases of Ebv positive samples (C666, GC98, GC100 and GC81) with type M+U MSP result, CpG site in LOXL1 promoter region was partially methylated. In the 2 cases of samples (SGC7901 and HGC27) with type U MSP result, methylation did not occur at CpG site in LOXL1 promoter region. Moreover, in the 3 cases of EBVaGC tissue (GC98, GC100 and GC81), some CPG sites of LOXL1 coding gene had two different methylated forms, i.e. methylation (C) and non-methylation (T) existed simultaneously.

In EBV related and negative gastric cancer tissues, the positive methylation rate of LOXL1 gene promoter in ENV negative gastric cancer tissue (68.2%, 15/22) was significantly higher than that of pericarcinomatous tissue. The positive rate (100%, 23/23) of gastric cancer methylation was significantly higher than that of EBV (χ²=6.41 (correction), P<0.05). The results are shown in Table 4.

### Table 4. LOXL1 gene methylation rates.

<table>
<thead>
<tr>
<th>Group</th>
<th>Positive (case)</th>
<th>Negative (case)</th>
<th>Methylation rate (χ%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBVaGC (n=23)</td>
<td>23</td>
<td>0</td>
<td>100%</td>
</tr>
<tr>
<td>EBVaGC matched para-carcinoma (n=23)</td>
<td>1</td>
<td>22</td>
<td>4.3%</td>
</tr>
<tr>
<td>EBVnGC (n=23)</td>
<td>15</td>
<td>7</td>
<td>68.2%</td>
</tr>
<tr>
<td>EBVnGC matched para-carcinoma (n=23)</td>
<td>2</td>
<td>20</td>
<td>9.1%</td>
</tr>
</tbody>
</table>

EBVaGC vs. EBVnGC matched para-carcinoma, χ²=42.17, P<0.01; EBVnGC vs. EBVnGC matched para-carcinoma, χ²=16.20, P<0.01; EBVaGC vs. EBVaGC, χ²=6.41, P<0.05.
3.3. Relationship Between LOXL1 Gene Methylation and Clinical Pathological Characteristics

LOXL1 gene methylation in gastric cancer tissue and the gender, age, pathological histology type, diseased site, lymphatic metastasis and EBV infection of patients were compared (Table 5). The result show that LOXL1 gene methylation was not significantly correlated with the gender, age, pathological histology type, diseased site and morbidity of lymphatic metastasis. Only the methylation rates differed significantly ($\chi^2=6.41\text{ (correction), } P<0.05$).

Table 5. Relationship between LOXL1 gene methylation and the clinical pathological characteristics of gastric cancer patients.

<table>
<thead>
<tr>
<th>Item</th>
<th>Case No.</th>
<th>Positive</th>
<th>Negative</th>
<th>Positive rate (%)</th>
<th>$\chi^2$</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>39</td>
<td>32</td>
<td>7</td>
<td>82.1</td>
<td>1.28</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Female</td>
<td>6</td>
<td>6</td>
<td>0</td>
<td>100</td>
<td>0.46</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$&lt; 50$</td>
<td>11</td>
<td>10</td>
<td>1</td>
<td>90.9</td>
<td>0.17</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>$\geq 50$</td>
<td>34</td>
<td>28</td>
<td>6</td>
<td>82.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pathological type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Highly and mediumly differentiated adenocarcinoma</td>
<td>9</td>
<td>8</td>
<td>1</td>
<td>88.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lowly differentiated adenocarcinoma</td>
<td>36</td>
<td>30</td>
<td>6</td>
<td>83.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastric cardia</td>
<td>4</td>
<td>4</td>
<td>0</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastric body</td>
<td>8</td>
<td>6</td>
<td>2</td>
<td>75.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastric antrum</td>
<td>20</td>
<td>16</td>
<td>4</td>
<td>80.0</td>
<td>2.37</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>More than 2 sites</td>
<td>10</td>
<td>9</td>
<td>1</td>
<td>90.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastric stump</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphatic metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>28</td>
<td>24</td>
<td>4</td>
<td>85.7</td>
<td>0.09</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>No</td>
<td>17</td>
<td>14</td>
<td>3</td>
<td>82.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBV positive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBVaGC</td>
<td>23</td>
<td>23</td>
<td>0</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBVnGC</td>
<td>22</td>
<td>15</td>
<td>7</td>
<td>68.2</td>
<td>6.41</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

*EBVaGC and EBVnGC, $\chi^2=6.41, P<0.05$.

4. Discussion

EBV infection is closely associated with the occurrence of some gastric cancers. The results of in-situ hybridization showed that EBV could be detected in almost all tumor cells in EBVaGC tissues, indicating that EBV infection occurred in the early gastric carcinogenesis and tumor originated from the monoclonal growth of EBV infected cells [11]. Further studies have shown that compared with EBVnGC, EBVaGC has unique clinical pathological features. For example, the onset of EBVaGC presents a low-aging tendency, and the diseased part is commonly in the gastric body or cardia region at gastric fundus. The pathological type is mainly tubular adenocarcinoma or poorly differentiated adenocarcinoma. In terms of histopathological type, diffuse gastric cancer occurs more frequently than intestinal gastric cancer with low lymphatic metastasis rate and desirable prognosis [12]. The expression of virus coding gene of EBVaGc is not identical to that of EBV-related tumors such as NPC and Burkitt’s lymphoma. For instance, recognized EBV cell transformation gene, i.e. latent membrane protein (LMP) 1 coding gene, is not expressed in EbVaGC [13]. Its differences from EBVnGC and other EBV-related tumors suggest that EBVaGC has a unique formation mechanism [14].

DNA methylation is the most cutting-edge epigenetic mechanism that has been extensively accessed, in which the role of methylation-based epigenetic change in tumorigenesis is of the greatest concern. In addition to mutation and deletion, the hypermethylation of tumor suppressor gene promoter is considered to determine the functional inactivation of tumor suppressor gene, which plays an important role in tumorigenesis and tumor evolution [15]. Currently, studies on EBVaGC methylation have been focusing on the detection of methylation status of known genes at DNA level, while methylation silenced cancer suppressor genes caused by EBV infection are rarely screened and identified. [16]. DNA methylation is not involved in the change of DNA sequence, therefore this change is reversible, suggesting that the hypermethylation status in gene promoter region can be eliminated by demethylation to reactivate the silenced genes, especially tumor suppressor ones [17]. Nucleoid methyltransferase inhibitors represented by 5-Aza-CdR have been widely used to reverse the aberrant methylation of tumor cells, induce the re-expression of methylation silenced tumor suppressor genes and inhibit the growth of tumor cells, thus killing tumor cells [18]. EBV positive and negative gastric cancer cell lines were selected in this study as the object and treated with 5-Aza-CdR to re-express methylation silenced tumor suppressor genes. In the meantime, an untreated control group was established, the total cellular RNA of the experimental and control groups was prepared, and then the gene expression level was detected by high-throughput whole genome microarray expression profile chip to screen the silent cancer suppressor genes due to methylation. Then the methylation of these genes was verified and analyzed to identify methylation silenced cancer suppressor genes specific to EBV positive gastric cancer cell lines. Hence, the methylation status of target genes in EBVaGC and EBVnGC tissues was further detected and compared to analyze the relationship between the methylation of identified cancer suppressor genes and clinical pathological features so as to clarify the action mechanism of EBV infection in EBV positive cell lines and EBVaGC tissue methylating candidate cancer suppressor genes, and to define EBVaGC specific apparent molecular genetic marker.

Agilent gene expression profile [19] experiment: a
comparative analysis was conducted on the differences of gene expression between 5-Aza-CdR treatment group and non-treatment group of EBV negative and positive gastric cancer cell lines. According to the different degrees of gene expression and SAS system and functional clues provided by relevant literatures, 6 differentially expressed genes (H19, LOXL1, ARM CX2, LXX, CDH3 and MMP7) were selected for real-time fluorescence quantitative PCR analysis to verify the results of gene chip [20]. The results show that 6 genes in three EBV positive gastric cancer cell lines with Aza treatment had different degrees of expression upregulation. Nevertheless, 5 genes (LOXL1, ARM CX2, LXX, CDH3 and MMP7) in EBV negative gastric cell line SGC7901 had undifferentiated expressions before and after Aza treatment, which is consistent with the result of gene chip. Only H19 gene had expression upregulation in EBV negative gastric cell line SGC7901 after treatment, which was different from the result of gene chip detection. The results above show that real-time fluorescence quantitative PCR accords with chip detection result, proving the reliability of gene chip result to some extent and indicating that hypermethylation of these genes is caused by EBV infection, i.e. silent genes involved by EBV may be related to the occurrence of EBV-related gastric cancers [21].

This study found that LOXL1 gene promoter was hypermethylated in EBV-related gastric cancer tissues, indicating that DNA methylation status in LOXL1 gene regulation region is an essential regulatory mechanism of gene expression [22]. The MSP results show that LOXL-1 promoter was fully methylated in EBV positive gastric cancer cell lines GT38 and PT, partially methylated in EBV positive cell lines (B95-8, Raji, GT39 and SNU719), and unmethylated in EBV negative gastric cancer cell lines SGC7901 and HGC27. The methylation rate of LOXL-1 promoter in EBV-related gastric cancer tissues was significantly higher than that in EBV negative gastric cancer tissues. The results above reveal that the LOXL-1 gene methylation in EBVaGC tissues was highly correlated to EBV infection, and LOXL-1 gene was the candidate methylation silenced cancer suppressor gene of EBVaGC [23].

DNMT introduces an activated methyl group into DNA chain with SAM as the donor and forms m5C through covalent binding with carbon potential of genome CpG binuclear general acid [24]. Methylation transferases include maintenance methylation transferase (DNMT1) and re-methylase (DNMT3a, DNMT3b). In the form of maintenance extensive methylation, these three enzymes have both overlapped and respective unique functions [25]. EBV is latently infected in tumor tissues. In EBV-related tumor tissues such as Burkitt lymphoma and NPC, EBV genome is hypermethylated and close to the expression of nuclear antigen (EBNA) 2~6 genes and rise phase genes through methylation of Wp and Cp promoter genes and rise phase gene promoters Zp and Rp, thus avoiding the killing effect of cytotoxicity T cell on EBV infected cells [26]. Some studies also hold that virus and host cells interact in EBV carcinogenesis [27]. EBV can induce host cell gene to aberrant methylation while developing self-defense via its own gene methylation, which results in cell cycle disorder and cell transformation, as well as promotes the occurrence and development of EBV-related tumors epigenetically. This study shows that EBVaGC methylation frequency and methylation density of promoter CpG island were much higher than those of EBVnGC, and hypermethylation was negatively correlated with the expression of cancer suppressor genes in EBVaGC tissues such as p16 and p73. EBV infection induced aberrant methylation in CpG island, thereby inactivating cancer suppressor genes. It might be a mechanism of EBV being involved in the occurrence of EBVaGC. However, it is still undefined how EBV induces the methylation of host cell cancer suppressor gene. LMP1 can interact with cell cycle regulatory gene through multiple mechanisms and thus promote cell proliferation and suppress cell apoptosis. LMP2 and LMP1 are commonly distributed on cell membrane with synergistic effects, but the specific function remains unclear yet. LMP2A might be related to transmembrane signaling. In EBV-infected B cells, LMP2A can block the Ca2+ passage of B cells and suppress virus entering the lytic cycle, thus maintaining the latency infection of EBV. However, the function in epithelial cells has not been determined [28].

The study above indicates that the expression of virus-associated genes up-regulated that of DNMTs by relevant signaling pathways, and finally induced aberrant methylation in CpG island, thus resulting in the inactivation of cancer suppressor genes. In EBV positive cell line and EBVaGC tissue, LOXL1 methylation degree was significantly higher than those of EBV negative cell line and EBVnGC tissue, inferring that EBV accounts for the DNA methylation in LOXL1 gene regulatory region and that LOXL1 gene might be the candidate methylation silenced cancer suppressor gene specific to EBVaGC.

In this study, EBV positive (PT, GT38 and SNU719) and negative (SGC7901) gastric cancer cell lines cultivated in vitro were treated with a demethylation reagent 5-Aza-CdR to extract the total cellular RNA before and after treatment. The results of gene chip were verified by real-time fluorescence quantitative PCR, and CpG island methylation in some gene promoter regions was detected by methylation specificity PCR (MSP) and hydroxyl sulphite genome sequencing method (BGS). The gene (LOXL1) with reported tumor suppressor function was selected as the candidate cancer suppressor gene. In EBV positive cell line and EBVaGC tissue, LOXL1 gene promoter region was hypermethylated and its methylation degree was significantly higher than those of EBV negative cell lines and EBVnGC tissue. Promoter CpG island had aberrant methylation and thus inactivated cancer suppressor gene.

5. Conclusion

In conclusion, the hypermethylation of cancer suppressor gene promoter governed the functional inactivation of cancer suppressor gene in addition to mutation and deficiency. EBV infection induced aberrant methylation of CpG island, which thus inactivated cancer suppressor gene. It might be a mechanism of EBV being involved in the occurrence of EBVaGC.
References


